RP2.H.iPSC.3
RIi009-A
General
Cell Line |
|
| hPSCreg name | RIi009-A |
| Cite as: | RIi009-A (RRID:CVCL_C916) |
| Alternative name(s) |
RP2.H.iPSC.3
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
LUMCi056-A-1 (LUMC0128iCRB01 heterozygote CRISPR corrected isogenic clone 02, iso02LUMC0128iCRB01) Donor's gene variants: CRB1, CRB1 Donor diseases: Retinitis Pigmentosa LUMCi055-A (CRB1 patient 117 compound heterozygous 2983G>T p.(Glu995*) c.1892A>G, p.(Tyr631Cys), LUMC0117iCRB01) Donor's gene variants: CRB1, CRB1 Donor diseases: Retinitis Pigmentosa LUMCi056-A (CRB1 patient 128 compound heterozygous c.2843G>A p.(Cys948Tyr) and c.3122T>C p.(Met1041Thr), LUMC0128iCRB01) Donor's gene variants: CRB1, CRB1 Donor diseases: Retinitis Pigmentosa UNEWi002-A (UNEW002Ai, PRPF31 AW) Donor's gene variants: PRPF31, PRPF31 Donor diseases: Retinitis pigmentosa ESi077-A (CABi001-A, PRPF31-MiPS4F3) Donor's gene variants: PRPF31, PRPF31 Donor diseases: Retinitis Pigmentosa |
| Last update | 30th August 2022 |
| User feedback | |
Provider |
|
| Generator |
Royan Institute (RI)
Contact:
Embryonic Stem Cell Biology |
| Derivation country | Iran |
External Databases |
|
| Cellosaurus | CVCL_C916 |
| Wikidata | Q54951130 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
Yes |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
| Disease associated phenotypes |
|
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | No |
| Please provide contact information of the holder of the original Donor Information Sheet. | |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | Yes |
| How may genetic information associated with the cell line be accessed? | |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
Reprogramming method |
|
| Vector type | Integrating |
| Vector | Virus (Retrovirus) |
| Genes | |
| Is the used vector excisable? |
Unknown |
| Absence of reprogramming vector(s)? |
Unknown |
| Reprogramming vectors silenced? | |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Surface coating | Matrigel/Geltrex | ||||||||||||||||||||||||
| CO2 Concentration | 5 % | ||||||||||||||||||||||||
| Medium |
Other medium:
Base medium: DMEM F/12
Main protein source: Knock-out serum replacement Serum concentration: 20 % Supplements
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| Alkaline Phosphatase |
Yes |
|
||||
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
|||
| SSEA-3 |
Yes |
|
||||
| SSEA-4 |
Yes |
|
||||
| TRA 1-60 |
Yes |
|
||||
| TRA 1-81 |
Yes |
|
||||
| SOX2 |
Yes |
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46XY
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.